Clinical Trial Update: MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial results update of MEN1611 in combination with trastuzumab, with or without fulvestrant, in metastatic breast cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• MEN1611 (MEN1611)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Menarini Group | Conditions: Advanced or Metastatic Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-06-26